What do systematic reviews say?

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

Paracetamol plus ibuprofen (oral or IV) showed no clear difference in failure of PDA closure after first course of treatment (assessed by… compared with ibuprofen plus placebo (oral or IV) or no intervention (low certainty).

• Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
  RR 0.77 [0.43, 1.36]
  2 studies · 111 participants
  Low

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

The review found no eligible studies for this question.

• Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paracetamol plus ibuprofen (oral or IV) vs ibuprofen plus placebo (oral or IV) or no intervention

Paracetamol plus ibuprofen (oral or IV) showed no clear difference in necrotizing enterocolitis during initial hospital stay (radiological… compared with ibuprofen plus placebo (oral or IV) or no intervention (low certainty).

• Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants 2022 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.45]
  1 study · 24 participants
  Low

Interventions (ibuprofen, tolfenamic acid) vs placebo

Interventions (ibuprofen, tolfenamic acid) showed no clear difference in reduction in painful menstruation compared with placebo (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 1 [0.11, 8.95]
  1 study · 20 participants
  Low

Interventions (ibuprofen, tolfenamic acid) vs placebo

It is very uncertain whether interventions (ibuprofen, tolfenamic acid) changes menstruation "more painful than normal" compared with placebo (very low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.71 [0.44, 1.44]
  1 study · 310 participants
  Very low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in gastrointestinal side effects (nausea) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 1.52 [0.53, 4.37]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg may leads to lower gastrointestinal side effects (vomiting) compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.19 [0.04, 0.97]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

Summary of findings table ‐ Ibuprofen 800 mg showed no clear difference in complete abortion rate compared with placebo (low certainty).

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  OR 0.69 [0.17, 2.85]
  1 study · 61 participants
  Low

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Ibuprofen 800 mg vs placebo

The review found no eligible studies for this question.

• Pain management for medical abortion before 14 weeks’ gestation 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) showed no clear difference in menstrual blood loss (alkaline hematin method) compared with placebo or active comparators (paracetamol, tranexamic acid); GRADE not reported.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 14.11
  Studies not reported
  GRADE not reported
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 0.3
  Studies not reported
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) showed no clear difference in duration of bleeding (menstrual diary) compared with placebo or active comparators (paracetamol, tranexamic acid); GRADE not reported.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 0.2
  Studies not reported
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found